Legacy Capital Group California Inc. Raises Holdings in Sanofi (NASDAQ:SNY)

Legacy Capital Group California Inc. boosted its stake in Sanofi (NASDAQ:SNY) by 4.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,495 shares of the company’s stock after purchasing an additional 384 shares during the period. Legacy Capital Group California Inc.’s holdings in Sanofi were worth $412,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SNY. Frazier Financial Advisors LLC purchased a new stake in shares of Sanofi during the fourth quarter worth about $28,000. Register Financial Advisors LLC bought a new position in Sanofi during the 1st quarter valued at approximately $29,000. Larson Financial Group LLC lifted its holdings in Sanofi by 480.8% in the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after buying an additional 500 shares during the period. McIlrath & Eck LLC lifted its holdings in Sanofi by 143.3% in the 4th quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock worth $30,000 after buying an additional 361 shares during the period. Finally, Johnson Financial Group Inc. bought a new stake in shares of Sanofi in the 4th quarter worth approximately $31,000. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Up 0.8 %

Shares of SNY traded up $0.45 on Wednesday, reaching $55.23. The stock had a trading volume of 1,706,693 shares, compared to its average volume of 2,108,165. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a 12-month low of $42.63 and a 12-month high of $55.72. The firm has a market capitalization of $139.88 billion, a price-to-earnings ratio of 27.60, a price-to-earnings-growth ratio of 1.56 and a beta of 0.59. The company has a 50-day simple moving average of $50.53 and a 200-day simple moving average of $48.92.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.95 earnings per share. Sell-side analysts predict that Sanofi will post 4.19 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on SNY. Argus upped their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Sanofi has an average rating of “Moderate Buy” and a consensus target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.